Sarepta Therapeutics, Inc.

NasdaqGS:SRPT Stok Raporu

Piyasa değeri: US$11.7b

Sarepta Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Sarepta Therapeutics CEO'su Doug Ingram, Jun2017 tarihinde atandı, in görev süresi 7.42 yıldır. in toplam yıllık tazminatı $ 1.66M olup, şirket hissesi ve opsiyonları dahil olmak üzere 48.1% maaş ve 51.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.41% ine doğrudan sahiptir ve bu hisseler $ 48.03M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.9 yıl ve 8.5 yıldır.

Anahtar bilgiler

Doug Ingram

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi48.1%
CEO görev süresi7.4yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi3.9yrs
Yönetim Kurulu ortalama görev süresi8.5yrs

Son yönetim güncellemeleri

Recent updates

Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

Oct 20
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

The Play On Sarepta Therapeutics

Sep 26

Sarepta Therapeutics Muscles Up In DMD Race

Sep 19

Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity

Jul 24

Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Jul 05
Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Sarepta Therapeutics: Navigating Elevidys Upside Potential

Jun 17

Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear

May 08
Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear

Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

May 05
Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Apr 15
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

Apr 11

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Feb 06
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

Jan 22

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jan 10
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Dec 20
There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Nov 29
Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Aug 08
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Apr 30
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Jan 17
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001

Sep 29

Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027

Sep 12

Sarepta says FDA lifted clinical hold on Duchenne candidate

Sep 06

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Aug 22
Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses

Aug 08

Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder

Jul 29

Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

May 09
Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

CEO Tazminat Analizi

Doug Ingram'un ücretlendirmesi Sarepta Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

US$47m

Mar 31 2024n/an/a

US$17m

Dec 31 2023US$2mUS$800k

-US$536m

Sep 30 2023n/an/a

-US$691m

Jun 30 2023n/an/a

-US$908m

Mar 31 2023n/an/a

-US$1b

Dec 31 2022US$125mUS$740k

-US$703m

Sep 30 2022n/an/a

-US$716m

Jun 30 2022n/an/a

-US$507m

Mar 31 2022n/an/a

-US$357m

Dec 31 2021US$2mUS$730k

-US$419m

Sep 30 2021n/an/a

-US$486m

Jun 30 2021n/an/a

-US$634m

Mar 31 2021n/an/a

-US$704m

Dec 31 2020US$1mUS$669k

-US$554m

Sep 30 2020n/an/a

-US$601m

Jun 30 2020n/an/a

-US$530m

Mar 31 2020n/an/a

-US$656m

Dec 31 2019US$1mUS$650k

-US$715m

Sep 30 2019n/an/a

-US$620m

Jun 30 2019n/an/a

-US$570m

Mar 31 2019n/an/a

-US$403m

Dec 31 2018US$1mUS$650k

-US$362m

Sep 30 2018n/an/a

-US$245m

Jun 30 2018n/an/a

-US$216m

Mar 31 2018n/an/a

-US$170m

Dec 31 2017US$57mUS$338k

-US$51m

Tazminat ve Piyasa: Doug 'nin toplam tazminatı ($USD 1.66M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 12.88M ).

Tazminat ve Kazançlar: Doug 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Doug Ingram (61 yo)

7.4yrs

Görev süresi

US$1,661,338

Tazminat

Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as an Independent Director of Rela...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Douglas Ingram
President7.4yrsUS$1.66m0.41%
$ 48.0m
Ian Estepan
Executive VP & CFO3.9yrsUS$3.71m0.036%
$ 4.2m
Bilal Arif
Executive VP & Chief Technical Operations Officer1.9yrsUS$3.52m0.018%
$ 2.1m
Louise Rodino-Klapac
Executive VP3.9yrsUS$3.72m0.076%
$ 8.9m
Ryan Brown
Executive VP3.9yrsUS$3.58m0.018%
$ 2.1m
Francesca Nolan
Executive Director of Investor Relations and Corporate Communicationsno dataVeri yokVeri yok
Alison Nasisi
Executive VP & Chief People Officer3.1yrsVeri yokVeri yok
Diane Berry
Executive VP and Chief of Global Policy & Advocacy Officer5.2yrsVeri yokVeri yok
Dallan Murray
Executive VP & Chief Customer Officer3.9yrsVeri yok0.023%
$ 2.7m
Will Tilton
Senior VP1.8yrsVeri yokVeri yok
Joseph Bratica
Controller & VP7.7yrsUS$911.89kVeri yok
Mary Jenkins
Senior Manager of Investor Relationsno dataVeri yokVeri yok

3.9yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: SRPT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Douglas Ingram
President7.4yrsUS$1.66m0.41%
$ 48.0m
M. Behrens
Independent Chairwoman15.7yrsUS$594.99k0.21%
$ 24.5m
Hans Wigzell
Chairman of Corporate Strategy Board & Independent Non-Employee Director14.4yrsUS$546.99k0.022%
$ 2.6m
Richard Barry
Independent Director9.4yrsUS$563.65k3.33%
$ 391.3m
Beverly Davidson
Member of Strategic & Scientific Advisory Board9.3yrsVeri yokVeri yok
Joy Cavagnaro
Member of Scientific Advisory Board5yrsVeri yokVeri yok
Louis Kunkel
Member of Strategic & Scientific Advisory Board9.3yrsVeri yokVeri yok
Claude Nicaise
Independent Non-Employee Director9.4yrsUS$553.34k0.017%
$ 2.0m
Kenneth Fischbeck
Member of Strategic & Scientific Advisory Board7.7yrsVeri yokVeri yok
Carsten Bonnemann
Member of Scientific Advisory Board4.9yrsVeri yokVeri yok
Matthew Wood
Member of Strategic & Scientific Advisory Board7.7yrsVeri yokVeri yok
Annemieke Aartsma-Rus
Member of Scientific Advisory Board5yrsVeri yokVeri yok

8.5yrs

Ortalama Görev Süresi

71yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SRPT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.5 yıldır).